Approach to the diagnosis and management of lipoprotein disorders

Khalid Alwaili, Khalid Alrasadi, Zuhier Awan, Jacques Genest

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Disorders of lipoprotein metabolism are frequently encountered in clinical practice. Although the severe genetic hyperlipidemias are relatively infrequent, prompt recognition and treatment can prevent complications, such as atherosclerosis and pancreatitis. The secondary dyslipidemias, due to medication or other metabolic disorders (hypothyroidism, renal or hepatic diseases), must be identified and treated. With the growing epidemic of obesity, dyslipidemias are a component of the metabolic syndrome. RECENT FINDINGS: The stratification of cardiovascular risk now includes family history and biomarkers of inflammation, especially high-sensitivity C-reactive protein, which enables sound clinical decision making. Lifelong hypercholesterolemia is strongly associated with increasing risk of atherosclerosis and coronary heart disease death, but the decision to treat pharmacologically depends on the absolute cardiovascular risk over the next 10 years. Clinical trial data support intensive treatment of patients at high cardiovascular risk or for the secondary prevention of recurrent coronary heart disease. The recently published JUPITER trial shows that patients with an elevated C-reactive protein benefit from treatment with a statin (rosuvastatin 20 mg) for primary prevention. SUMMARY: The current guidelines for the prevention of coronary artery disease will continue to focus on the determination of global risk, with intensive treatment aimed at the high-risk group. Family history and high-sensitivity C-reactive protein provide additional risk stratification.

Original languageEnglish
Pages (from-to)132-140
Number of pages9
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume16
Issue number2
DOIs
Publication statusPublished - Apr 2009

Fingerprint

Lipoproteins
C-Reactive Protein
Dyslipidemias
Coronary Disease
Atherosclerosis
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Primary Prevention
Therapeutics
Secondary Prevention
Hypothyroidism
Hypercholesterolemia
Hyperlipidemias
Pancreatitis
Coronary Artery Disease
Obesity
Biomarkers
Clinical Trials
Guidelines
Inflammation
Kidney

Keywords

  • Cardiovascular risk
  • Cholesterol
  • Dyslipidemia
  • Hyperlipidemia
  • Metabolic syndrome

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics
  • Medicine(all)

Cite this

Approach to the diagnosis and management of lipoprotein disorders. / Alwaili, Khalid; Alrasadi, Khalid; Awan, Zuhier; Genest, Jacques.

In: Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 16, No. 2, 04.2009, p. 132-140.

Research output: Contribution to journalArticle

@article{40cb6c39184d479687c9e982c4881c69,
title = "Approach to the diagnosis and management of lipoprotein disorders",
abstract = "PURPOSE OF REVIEW: Disorders of lipoprotein metabolism are frequently encountered in clinical practice. Although the severe genetic hyperlipidemias are relatively infrequent, prompt recognition and treatment can prevent complications, such as atherosclerosis and pancreatitis. The secondary dyslipidemias, due to medication or other metabolic disorders (hypothyroidism, renal or hepatic diseases), must be identified and treated. With the growing epidemic of obesity, dyslipidemias are a component of the metabolic syndrome. RECENT FINDINGS: The stratification of cardiovascular risk now includes family history and biomarkers of inflammation, especially high-sensitivity C-reactive protein, which enables sound clinical decision making. Lifelong hypercholesterolemia is strongly associated with increasing risk of atherosclerosis and coronary heart disease death, but the decision to treat pharmacologically depends on the absolute cardiovascular risk over the next 10 years. Clinical trial data support intensive treatment of patients at high cardiovascular risk or for the secondary prevention of recurrent coronary heart disease. The recently published JUPITER trial shows that patients with an elevated C-reactive protein benefit from treatment with a statin (rosuvastatin 20 mg) for primary prevention. SUMMARY: The current guidelines for the prevention of coronary artery disease will continue to focus on the determination of global risk, with intensive treatment aimed at the high-risk group. Family history and high-sensitivity C-reactive protein provide additional risk stratification.",
keywords = "Cardiovascular risk, Cholesterol, Dyslipidemia, Hyperlipidemia, Metabolic syndrome",
author = "Khalid Alwaili and Khalid Alrasadi and Zuhier Awan and Jacques Genest",
year = "2009",
month = "4",
doi = "10.1097/MED.0b013e328329135a",
language = "English",
volume = "16",
pages = "132--140",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Approach to the diagnosis and management of lipoprotein disorders

AU - Alwaili, Khalid

AU - Alrasadi, Khalid

AU - Awan, Zuhier

AU - Genest, Jacques

PY - 2009/4

Y1 - 2009/4

N2 - PURPOSE OF REVIEW: Disorders of lipoprotein metabolism are frequently encountered in clinical practice. Although the severe genetic hyperlipidemias are relatively infrequent, prompt recognition and treatment can prevent complications, such as atherosclerosis and pancreatitis. The secondary dyslipidemias, due to medication or other metabolic disorders (hypothyroidism, renal or hepatic diseases), must be identified and treated. With the growing epidemic of obesity, dyslipidemias are a component of the metabolic syndrome. RECENT FINDINGS: The stratification of cardiovascular risk now includes family history and biomarkers of inflammation, especially high-sensitivity C-reactive protein, which enables sound clinical decision making. Lifelong hypercholesterolemia is strongly associated with increasing risk of atherosclerosis and coronary heart disease death, but the decision to treat pharmacologically depends on the absolute cardiovascular risk over the next 10 years. Clinical trial data support intensive treatment of patients at high cardiovascular risk or for the secondary prevention of recurrent coronary heart disease. The recently published JUPITER trial shows that patients with an elevated C-reactive protein benefit from treatment with a statin (rosuvastatin 20 mg) for primary prevention. SUMMARY: The current guidelines for the prevention of coronary artery disease will continue to focus on the determination of global risk, with intensive treatment aimed at the high-risk group. Family history and high-sensitivity C-reactive protein provide additional risk stratification.

AB - PURPOSE OF REVIEW: Disorders of lipoprotein metabolism are frequently encountered in clinical practice. Although the severe genetic hyperlipidemias are relatively infrequent, prompt recognition and treatment can prevent complications, such as atherosclerosis and pancreatitis. The secondary dyslipidemias, due to medication or other metabolic disorders (hypothyroidism, renal or hepatic diseases), must be identified and treated. With the growing epidemic of obesity, dyslipidemias are a component of the metabolic syndrome. RECENT FINDINGS: The stratification of cardiovascular risk now includes family history and biomarkers of inflammation, especially high-sensitivity C-reactive protein, which enables sound clinical decision making. Lifelong hypercholesterolemia is strongly associated with increasing risk of atherosclerosis and coronary heart disease death, but the decision to treat pharmacologically depends on the absolute cardiovascular risk over the next 10 years. Clinical trial data support intensive treatment of patients at high cardiovascular risk or for the secondary prevention of recurrent coronary heart disease. The recently published JUPITER trial shows that patients with an elevated C-reactive protein benefit from treatment with a statin (rosuvastatin 20 mg) for primary prevention. SUMMARY: The current guidelines for the prevention of coronary artery disease will continue to focus on the determination of global risk, with intensive treatment aimed at the high-risk group. Family history and high-sensitivity C-reactive protein provide additional risk stratification.

KW - Cardiovascular risk

KW - Cholesterol

KW - Dyslipidemia

KW - Hyperlipidemia

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=66149088876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149088876&partnerID=8YFLogxK

U2 - 10.1097/MED.0b013e328329135a

DO - 10.1097/MED.0b013e328329135a

M3 - Article

C2 - 19306526

AN - SCOPUS:66149088876

VL - 16

SP - 132

EP - 140

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

IS - 2

ER -